Journal
GROWTH HORMONE & IGF RESEARCH
Volume 60-61, Issue -, Pages -Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ghir.2021.101430
Keywords
Pituitary carcinoma; Acromegaly; Somatotroph adenoma
Categories
Ask authors/readers for more resources
Pituitary carcinomas are rare tumors that are difficult to distinguish from aggressive pituitary adenomas. Treatment options include debulking surgery, radiotherapy, or chemotherapy, but outcomes are typically poor. Further studies are needed to identify predictive markers for metastatic potential.
Objective: Pituitary carcinoma is a rare tumor, defined as a tumor of adenohypophyseal cells with systemic or craniospinal metastasis. We present a case of a growth hormone (GH)-secreting pituitary carcinoma with a review of literature to better characterize this disease. Design: Case report and literature review of 25 cases of GH-secreting pituitary carcinomas Results: The age of diagnosis of GH-secreting carcinomas ranged 24-69 years old with a mean age of 44.4 with 52% of cases present in females. Mean latency period between diagnosis of acromegaly and transition to pituitary carcinoma was 11.4 years with mean survival being 3.4 years. Conclusion: Growth hormone (GH)-secreting pituitary carcinomas are rare and hard to distinguish from aggressive pituitary adenomas. From review of literature, treatment options include debulking surgery, radiotherapy, or chemotherapy with dismal outcomes. There are no diagnostic markers or features which can predict metastatic progression of these tumors. Future studies with genomic landscapes and relevant tumor markers are needed to identify pituitary tumors most likely to metastasize.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available